Oppenheimer Initiates Coverage On Silk Road Medical with Outperform Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia initiates coverage on Silk Road Medical (NASDAQ:SILK) with an Outperform rating and announces a price target of $30.

September 06, 2023 | 8:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Silk Road Medical with an Outperform rating and a price target of $30.
The Outperform rating from Oppenheimer indicates that the analyst expects Silk Road Medical to do better than the market average. This positive outlook, coupled with a price target of $30, suggests potential upside for the stock, which could drive its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100